| Literature DB >> 30406946 |
Ninna Bager1, Kristian L Juul-Dam1, Julie D Sandahl1, Jonas Abrahamsson2, Berna Beverloo3, Eveline S J M de Bont4, Shau-Yin Ha5, Kirsi Jahnukainen6, Ólafur G Jónsson7, Gertjan L Kaspers8, Zhanna Kovalova9, Birgitte Lausen10, Barbara De Moerloose11, Ulrika Noren-Nyström12, Josefine Palle13, Kadri Saks14, Bernward Zeller15, Eigil Kjeldsen16, Henrik Hasle1.
Abstract
Data on occurrence, genetic characteristics and prognostic impact of complex and monosomal karyotype (CK/MK) in children with acute myeloid leukaemia (AML) are scarce. We studied CK and MK in a large unselected cohort of childhood AML patients diagnosed and treated according to Nordic Society for Paediatric Haematology and Oncology (NOPHO)-AML protocols 1993-2015. In total, 800 patients with de novo AML were included. CK was found in 122 (15%) and MK in 41 (5%) patients. CK and MK patients were young (median age 2·1 and 3·3 years, respectively) and frequently had FAB M7 morphology (24% and 22%, respectively). Refractory disease was more common in MK patients (15% vs. 4%) and stem cell transplantation in first complete remission was more frequent (32% vs. 19%) compared with non-CK/non-MK patients. CK showed no association with refractory disease but was an independent predictor of an inferior event-free survival (EFS; hazard ratio [HR] 1·43, P = 0·03) and overall survival (OS; HR 1·48, P = 0·01). MK was associated with a poor EFS (HR 1·57, P = 0·03) but did not show an inferior OS compared to non-MK patients (HR 1·14, P = 0·62). In a large paediatric cohort, we characterized AML with non-recurrent abnormal karyotype and unravelled the adverse impact of CK and MK on prognosis.Entities:
Keywords: Acute myeloid leukaemia; complex karyotype; monosomal karyotype; paediatrics; refractory disease
Mesh:
Year: 2018 PMID: 30406946 DOI: 10.1111/bjh.15587
Source DB: PubMed Journal: Br J Haematol ISSN: 0007-1048 Impact factor: 6.998